Document is current

Any future updates will be listed below

15. Recombinant human hyaluronidase pretreatment of CSII cannula sites provides comparable glycemic control with reduced hypoglycemia in T1DM compared to usual CSII (85-LB)

Crossref DOI link: https://doi.org/10.1007/s12467-014-0040-3

Published Online: 2014-11-25

Published Print: 2014-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark